nodes	percent_of_prediction	percent_of_DWPC	metapath
Etoricoxib—CYP1A2—Pentoxifylline—systemic scleroderma	0.0914	0.222	CbGbCtD
Etoricoxib—CYP1A2—Leflunomide—systemic scleroderma	0.0872	0.212	CbGbCtD
Etoricoxib—CYP2C9—Leflunomide—systemic scleroderma	0.0786	0.191	CbGbCtD
Etoricoxib—CYP2D6—Captopril—systemic scleroderma	0.0564	0.137	CbGbCtD
Etoricoxib—CYP2C19—Prednisone—systemic scleroderma	0.0467	0.114	CbGbCtD
Etoricoxib—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0282	0.0687	CbGbCtD
Etoricoxib—CYP2C9—cardial valve—systemic scleroderma	0.0238	0.285	CbGeAlD
Etoricoxib—CYP3A4—Prednisone—systemic scleroderma	0.0226	0.0549	CbGbCtD
Etoricoxib—MAPK14—blood vessel—systemic scleroderma	0.00843	0.101	CbGeAlD
Etoricoxib—PTGS2—skeletal joint—systemic scleroderma	0.00744	0.0893	CbGeAlD
Etoricoxib—MAPK14—connective tissue—systemic scleroderma	0.00432	0.0519	CbGeAlD
Etoricoxib—MAPK14—smooth muscle tissue—systemic scleroderma	0.00396	0.0475	CbGeAlD
Etoricoxib—MAPK14—skin of body—systemic scleroderma	0.0039	0.0469	CbGeAlD
Etoricoxib—MAPK14—TSLP Signaling Pathway—TNFSF4—systemic scleroderma	0.00329	0.0497	CbGpPWpGaD
Etoricoxib—PTGS2—Fluocinonide—Mometasone—systemic scleroderma	0.00327	0.624	CbGdCrCtD
Etoricoxib—MAPK14—digestive system—systemic scleroderma	0.00312	0.0375	CbGeAlD
Etoricoxib—PTGS2—artery—systemic scleroderma	0.00311	0.0374	CbGeAlD
Etoricoxib—MAPK14—tendon—systemic scleroderma	0.00297	0.0357	CbGeAlD
Etoricoxib—PTGS2—endothelium—systemic scleroderma	0.00263	0.0316	CbGeAlD
Etoricoxib—MAPK14—lung—systemic scleroderma	0.00261	0.0313	CbGeAlD
Etoricoxib—MAPK14—Rac1/Pak1/p38/MMP-2 pathway—TNIP1—systemic scleroderma	0.00248	0.0375	CbGpPWpGaD
Etoricoxib—PTGS2—blood vessel—systemic scleroderma	0.00243	0.0291	CbGeAlD
Etoricoxib—MAPK14—VEGFR3 signaling in lymphatic endothelium—COL1A2—systemic scleroderma	0.00209	0.0316	CbGpPWpGaD
Etoricoxib—PTGS2—Fluticasone Propionate—Mometasone—systemic scleroderma	0.00198	0.376	CbGdCrCtD
Etoricoxib—MAPK14—NOD1/2 Signaling Pathway—TNFAIP3—systemic scleroderma	0.0015	0.0226	CbGpPWpGaD
Etoricoxib—MAPK14—Regulation of p38-alpha and p38-beta—BLK—systemic scleroderma	0.00148	0.0223	CbGpPWpGaD
Etoricoxib—CYP2C19—digestive system—systemic scleroderma	0.00133	0.0159	CbGeAlD
Etoricoxib—MAPK14—CD40/CD40L signaling—TNFAIP3—systemic scleroderma	0.00133	0.0201	CbGpPWpGaD
Etoricoxib—MAPK14—p73 transcription factor network—GDF15—systemic scleroderma	0.00128	0.0194	CbGpPWpGaD
Etoricoxib—PTGS2—connective tissue—systemic scleroderma	0.00124	0.0149	CbGeAlD
Etoricoxib—MAPK14—IL4-mediated signaling events—SELP—systemic scleroderma	0.00115	0.0173	CbGpPWpGaD
Etoricoxib—PTGS2—smooth muscle tissue—systemic scleroderma	0.00114	0.0137	CbGeAlD
Etoricoxib—MAPK14—Physiological and Pathological Hypertrophy  of the Heart—EDN1—systemic scleroderma	0.00113	0.0171	CbGpPWpGaD
Etoricoxib—PTGS2—skin of body—systemic scleroderma	0.00112	0.0135	CbGeAlD
Etoricoxib—CYP1A2—digestive system—systemic scleroderma	0.00108	0.013	CbGeAlD
Etoricoxib—CYP2C9—digestive system—systemic scleroderma	0.00103	0.0124	CbGeAlD
Etoricoxib—MAPK14—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—TNFAIP3—systemic scleroderma	0.00102	0.0154	CbGpPWpGaD
Etoricoxib—MAPK14—IL4-mediated signaling events—COL1A2—systemic scleroderma	0.00101	0.0153	CbGpPWpGaD
Etoricoxib—MAPK14—TSLP Signaling Pathway—STAT4—systemic scleroderma	0.00101	0.0152	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—AIF1—systemic scleroderma	0.00101	0.0152	CbGpPWpGaD
Etoricoxib—MAPK14—Endothelins—COL1A2—systemic scleroderma	0.000997	0.0151	CbGpPWpGaD
Etoricoxib—MAPK14—Regulation of mRNA stability by proteins that bind AU-rich elements—TNFSF13—systemic scleroderma	0.000991	0.015	CbGpPWpGaD
Etoricoxib—CYP2E1—digestive system—systemic scleroderma	0.000975	0.0117	CbGeAlD
Etoricoxib—MAPK14—IL12-mediated signaling events—CD247—systemic scleroderma	0.000941	0.0142	CbGpPWpGaD
Etoricoxib—CYP2E1—tendon—systemic scleroderma	0.000928	0.0111	CbGeAlD
Etoricoxib—MAPK14—Thromboxane A2 receptor signaling—BLK—systemic scleroderma	0.000921	0.0139	CbGpPWpGaD
Etoricoxib—MAPK14—BCR signaling pathway—CSK—systemic scleroderma	0.000917	0.0139	CbGpPWpGaD
Etoricoxib—CYP1A2—lung—systemic scleroderma	0.000905	0.0109	CbGeAlD
Etoricoxib—MAPK14—Interferon type I signaling pathways—STAT4—systemic scleroderma	0.000902	0.0136	CbGpPWpGaD
Etoricoxib—PTGS2—digestive system—systemic scleroderma	0.000898	0.0108	CbGeAlD
Etoricoxib—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—MMP1—systemic scleroderma	0.000868	0.0131	CbGpPWpGaD
Etoricoxib—PTGS2—tendon—systemic scleroderma	0.000855	0.0103	CbGeAlD
Etoricoxib—MAPK14—CD40/CD40L signaling—CD40LG—systemic scleroderma	0.000835	0.0126	CbGpPWpGaD
Etoricoxib—MAPK14—IL12-mediated signaling events—STAT4—systemic scleroderma	0.000829	0.0125	CbGpPWpGaD
Etoricoxib—CYP2E1—lung—systemic scleroderma	0.000815	0.00978	CbGeAlD
Etoricoxib—CYP3A4—digestive system—systemic scleroderma	0.000785	0.00942	CbGeAlD
Etoricoxib—CYP2D6—digestive system—systemic scleroderma	0.000772	0.00927	CbGeAlD
Etoricoxib—MAPK14—TGF-beta Signaling Pathway—SMAD7—systemic scleroderma	0.000756	0.0114	CbGpPWpGaD
Etoricoxib—PTGS2—lung—systemic scleroderma	0.00075	0.009	CbGeAlD
Etoricoxib—MAPK14—Angiogenesis—NOS3—systemic scleroderma	0.000712	0.0108	CbGpPWpGaD
Etoricoxib—MAPK14—Glucocorticoid receptor regulatory network—IL13—systemic scleroderma	0.000691	0.0104	CbGpPWpGaD
Etoricoxib—MAPK14—TCR Signaling Pathway—CD247—systemic scleroderma	0.000681	0.0103	CbGpPWpGaD
Etoricoxib—MAPK14—Structural Pathway of Interleukin 1 (IL-1)—IL1A—systemic scleroderma	0.000678	0.0103	CbGpPWpGaD
Etoricoxib—MAPK14—Toll-like Receptor Signaling Pathway—IRF5—systemic scleroderma	0.000644	0.00975	CbGpPWpGaD
Etoricoxib—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—systemic scleroderma	0.000634	0.00959	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000631	0.00955	CbGpPWpGaD
Etoricoxib—MAPK14—Senescence and Autophagy in Cancer—IRF5—systemic scleroderma	0.00063	0.00952	CbGpPWpGaD
Etoricoxib—PTGS2—Prostaglandin Synthesis and Regulation—EDN1—systemic scleroderma	0.000624	0.00944	CbGpPWpGaD
Etoricoxib—MAPK14—IL-1 signaling pathway—IL1A—systemic scleroderma	0.000598	0.00905	CbGpPWpGaD
Etoricoxib—MAPK14—B Cell Receptor Signaling Pathway—BLK—systemic scleroderma	0.000593	0.00897	CbGpPWpGaD
Etoricoxib—MAPK14—Angiogenesis—MMP9—systemic scleroderma	0.000571	0.00864	CbGpPWpGaD
Etoricoxib—MAPK14—TGF-beta Signaling Pathway—COL1A2—systemic scleroderma	0.000552	0.00834	CbGpPWpGaD
Etoricoxib—MAPK14—IL4-mediated signaling events—CD40LG—systemic scleroderma	0.00054	0.00817	CbGpPWpGaD
Etoricoxib—MAPK14—Endothelins—EDN1—systemic scleroderma	0.00054	0.00816	CbGpPWpGaD
Etoricoxib—MAPK14—Toll Like Receptor 4 (TLR4) Cascade—ITGAM—systemic scleroderma	0.000534	0.00807	CbGpPWpGaD
Etoricoxib—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—systemic scleroderma	0.000527	0.00798	CbGpPWpGaD
Etoricoxib—MAPK14—TWEAK Signaling Pathway—CCL2—systemic scleroderma	0.00051	0.00772	CbGpPWpGaD
Etoricoxib—PTGS2—C-MYB transcription factor network—COL1A2—systemic scleroderma	0.000506	0.00765	CbGpPWpGaD
Etoricoxib—MAPK14—Regulation of toll-like receptor signaling pathway—IRF5—systemic scleroderma	0.000503	0.00761	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—TNFSF13—systemic scleroderma	0.000491	0.00743	CbGpPWpGaD
Etoricoxib—MAPK14—Monoamine Transport—IL1B—systemic scleroderma	0.000481	0.00728	CbGpPWpGaD
Etoricoxib—MAPK14—Toll-Like Receptors Cascades—ITGAM—systemic scleroderma	0.000475	0.00719	CbGpPWpGaD
Etoricoxib—MAPK14—Metabolism of mRNA—TNFSF13—systemic scleroderma	0.000469	0.00709	CbGpPWpGaD
Etoricoxib—CYP2C19—Melatonin metabolism and effects—EDN1—systemic scleroderma	0.000466	0.00705	CbGpPWpGaD
Etoricoxib—MAPK14—Endothelins—MMP1—systemic scleroderma	0.000454	0.00686	CbGpPWpGaD
Etoricoxib—MAPK14—EGF/EGFR Signaling Pathway—CSK—systemic scleroderma	0.000452	0.00684	CbGpPWpGaD
Etoricoxib—MAPK14—Regulation of toll-like receptor signaling pathway—TNFAIP3—systemic scleroderma	0.00045	0.00681	CbGpPWpGaD
Etoricoxib—MAPK14—Oncostatin M Signaling Pathway—MMP1—systemic scleroderma	0.000443	0.00669	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—SELP—systemic scleroderma	0.000438	0.00662	CbGpPWpGaD
Etoricoxib—MAPK14—MicroRNAs in cardiomyocyte hypertrophy—EDN1—systemic scleroderma	0.000429	0.00649	CbGpPWpGaD
Etoricoxib—CYP2D6—Melatonin metabolism and effects—EDN1—systemic scleroderma	0.000429	0.00648	CbGpPWpGaD
Etoricoxib—MAPK14—Angiopoietin receptor Tie2-mediated signaling—MMP2—systemic scleroderma	0.000422	0.00639	CbGpPWpGaD
Etoricoxib—MAPK14—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	0.000415	0.00628	CbGpPWpGaD
Etoricoxib—MAPK14—IL-1 signaling pathway—CCL2—systemic scleroderma	0.000411	0.00622	CbGpPWpGaD
Etoricoxib—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—systemic scleroderma	0.00041	0.0062	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—RHOB—systemic scleroderma	0.000409	0.00618	CbGpPWpGaD
Etoricoxib—MAPK14—TCR Signaling Pathway—IL1A—systemic scleroderma	0.000403	0.0061	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000403	0.0061	CbGpPWpGaD
Etoricoxib—MAPK14—Metabolism of RNA—TNFSF13—systemic scleroderma	0.000401	0.00607	CbGpPWpGaD
Etoricoxib—MAPK14—Angiopoietin receptor Tie2-mediated signaling—NOS3—systemic scleroderma	0.000396	0.00598	CbGpPWpGaD
Etoricoxib—MAPK14—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	0.000387	0.00586	CbGpPWpGaD
Etoricoxib—MAPK14—ATF-2 transcription factor network—MMP2—systemic scleroderma	0.00037	0.0056	CbGpPWpGaD
Etoricoxib—MAPK14—Glucocorticoid receptor regulatory network—MMP1—systemic scleroderma	0.000367	0.00556	CbGpPWpGaD
Etoricoxib—MAPK14—TWEAK Signaling Pathway—MMP9—systemic scleroderma	0.000365	0.00552	CbGpPWpGaD
Etoricoxib—CYP1A2—Melatonin metabolism and effects—EDN1—systemic scleroderma	0.000363	0.00549	CbGpPWpGaD
Etoricoxib—MAPK14—Thromboxane A2 receptor signaling—NOS3—systemic scleroderma	0.000361	0.00547	CbGpPWpGaD
Etoricoxib—MAPK14—Oncostatin M Signaling Pathway—CCL2—systemic scleroderma	0.00036	0.00544	CbGpPWpGaD
Etoricoxib—MAPK14—Senescence and Autophagy in Cancer—IL1A—systemic scleroderma	0.000357	0.00539	CbGpPWpGaD
Etoricoxib—MAPK14—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	0.000353	0.00534	CbGpPWpGaD
Etoricoxib—MAPK14—AGE/RAGE pathway—MMP2—systemic scleroderma	0.000338	0.00512	CbGpPWpGaD
Etoricoxib—MAPK14—AGE/RAGE pathway—NOS3—systemic scleroderma	0.000317	0.00479	CbGpPWpGaD
Etoricoxib—MAPK14—IL-1 signaling pathway—IL1B—systemic scleroderma	0.000312	0.00472	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling events mediated by VEGFR1 and VEGFR2—NOS3—systemic scleroderma	0.000309	0.00468	CbGpPWpGaD
Etoricoxib—MAPK14—FGF signaling pathway—MMP9—systemic scleroderma	0.000299	0.00452	CbGpPWpGaD
Etoricoxib—MAPK14—IL12-mediated signaling events—IL1B—systemic scleroderma	0.000291	0.0044	CbGpPWpGaD
Etoricoxib—MAPK14—Leptin signaling pathway—NOS3—systemic scleroderma	0.000286	0.00433	CbGpPWpGaD
Etoricoxib—MAPK14—Platelet homeostasis—NOS3—systemic scleroderma	0.000277	0.00419	CbGpPWpGaD
Etoricoxib—Pruritus—Captopril—systemic scleroderma	0.000259	0.000597	CcSEcCtD
Etoricoxib—Constipation—Leflunomide—systemic scleroderma	0.000258	0.000594	CcSEcCtD
Etoricoxib—Pain—Leflunomide—systemic scleroderma	0.000258	0.000594	CcSEcCtD
Etoricoxib—Infection—Lisinopril—systemic scleroderma	0.000258	0.000593	CcSEcCtD
Etoricoxib—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000257	0.000593	CcSEcCtD
Etoricoxib—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000257	0.000591	CcSEcCtD
Etoricoxib—Somnolence—Mycophenolic acid—systemic scleroderma	0.000256	0.000589	CcSEcCtD
Etoricoxib—Agitation—Mycophenolate mofetil—systemic scleroderma	0.000256	0.000589	CcSEcCtD
Etoricoxib—Shock—Lisinopril—systemic scleroderma	0.000255	0.000588	CcSEcCtD
Etoricoxib—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000254	0.000586	CcSEcCtD
Etoricoxib—MAPK14—AGE/RAGE pathway—MMP9—systemic scleroderma	0.000254	0.00385	CbGpPWpGaD
Etoricoxib—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000254	0.000585	CcSEcCtD
Etoricoxib—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000253	0.000584	CcSEcCtD
Etoricoxib—Abdominal pain—Azathioprine—systemic scleroderma	0.000253	0.000582	CcSEcCtD
Etoricoxib—Skin disorder—Lisinopril—systemic scleroderma	0.000252	0.00058	CcSEcCtD
Etoricoxib—MAPK14—TGF-beta Signaling Pathway—MMP1—systemic scleroderma	0.000251	0.0038	CbGpPWpGaD
Etoricoxib—Diarrhoea—Captopril—systemic scleroderma	0.000251	0.000577	CcSEcCtD
Etoricoxib—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.00025	0.000576	CcSEcCtD
Etoricoxib—MAPK14—Cardiac Progenitor Differentiation—TGFB1—systemic scleroderma	0.00025	0.00378	CbGpPWpGaD
Etoricoxib—Feeling abnormal—Leflunomide—systemic scleroderma	0.000249	0.000573	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000249	0.000572	CcSEcCtD
Etoricoxib—Fatigue—Mycophenolic acid—systemic scleroderma	0.000248	0.000572	CcSEcCtD
Etoricoxib—Nausea—Mometasone—systemic scleroderma	0.000248	0.00057	CcSEcCtD
Etoricoxib—Anorexia—Lisinopril—systemic scleroderma	0.000247	0.000569	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000247	0.000568	CcSEcCtD
Etoricoxib—Weight increased—Prednisone—systemic scleroderma	0.000247	0.000568	CcSEcCtD
Etoricoxib—Pain—Mycophenolic acid—systemic scleroderma	0.000246	0.000567	CcSEcCtD
Etoricoxib—Constipation—Mycophenolic acid—systemic scleroderma	0.000246	0.000567	CcSEcCtD
Etoricoxib—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000246	0.000567	CcSEcCtD
Etoricoxib—MAPK14—MAPK Signaling Pathway—IL1A—systemic scleroderma	0.000245	0.0037	CbGpPWpGaD
Etoricoxib—Hyperglycaemia—Prednisone—systemic scleroderma	0.000244	0.000563	CcSEcCtD
Etoricoxib—MAPK14—Leptin signaling pathway—IL1B—systemic scleroderma	0.000243	0.00368	CbGpPWpGaD
Etoricoxib—Cough—Mycophenolate mofetil—systemic scleroderma	0.000243	0.000559	CcSEcCtD
Etoricoxib—MAPK14—Corticotropin-releasing hormone—NOS3—systemic scleroderma	0.000243	0.00367	CbGpPWpGaD
Etoricoxib—MAPK14—Cardiac Hypertrophic Response—TGFB1—systemic scleroderma	0.000242	0.00367	CbGpPWpGaD
Etoricoxib—Dizziness—Captopril—systemic scleroderma	0.000242	0.000558	CcSEcCtD
Etoricoxib—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.00024	0.000554	CcSEcCtD
Etoricoxib—Urticaria—Leflunomide—systemic scleroderma	0.00024	0.000552	CcSEcCtD
Etoricoxib—Abdominal pain—Leflunomide—systemic scleroderma	0.000239	0.000549	CcSEcCtD
Etoricoxib—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000238	0.000548	CcSEcCtD
Etoricoxib—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000237	0.000546	CcSEcCtD
Etoricoxib—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000237	0.000546	CcSEcCtD
Etoricoxib—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000237	0.000546	CcSEcCtD
Etoricoxib—Myocardial infarction—Prednisone—systemic scleroderma	0.000237	0.000545	CcSEcCtD
Etoricoxib—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000237	0.000545	CcSEcCtD
Etoricoxib—Breast disorder—Methotrexate—systemic scleroderma	0.000237	0.000545	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000236	0.000544	CcSEcCtD
Etoricoxib—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000236	0.000544	CcSEcCtD
Etoricoxib—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000236	0.000543	CcSEcCtD
Etoricoxib—Hypersensitivity—Azathioprine—systemic scleroderma	0.000236	0.000542	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000235	0.000542	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000235	0.000542	CcSEcCtD
Etoricoxib—Insomnia—Lisinopril—systemic scleroderma	0.000235	0.00054	CcSEcCtD
Etoricoxib—Vomiting—Captopril—systemic scleroderma	0.000233	0.000536	CcSEcCtD
Etoricoxib—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000232	0.000534	CcSEcCtD
Etoricoxib—Dyspnoea—Lisinopril—systemic scleroderma	0.000231	0.000532	CcSEcCtD
Etoricoxib—Rash—Captopril—systemic scleroderma	0.000231	0.000532	CcSEcCtD
Etoricoxib—Dermatitis—Captopril—systemic scleroderma	0.000231	0.000531	CcSEcCtD
Etoricoxib—Somnolence—Lisinopril—systemic scleroderma	0.000231	0.000531	CcSEcCtD
Etoricoxib—Headache—Captopril—systemic scleroderma	0.000229	0.000528	CcSEcCtD
Etoricoxib—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000229	0.000528	CcSEcCtD
Etoricoxib—Dyspepsia—Lisinopril—systemic scleroderma	0.000228	0.000526	CcSEcCtD
Etoricoxib—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000228	0.000524	CcSEcCtD
Etoricoxib—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000227	0.000523	CcSEcCtD
Etoricoxib—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000227	0.000523	CcSEcCtD
Etoricoxib—Infection—Mycophenolate mofetil—systemic scleroderma	0.000226	0.00052	CcSEcCtD
Etoricoxib—MAPK14—Cellular Senescence—IL1A—systemic scleroderma	0.000226	0.00341	CbGpPWpGaD
Etoricoxib—Decreased appetite—Lisinopril—systemic scleroderma	0.000225	0.000519	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000224	0.000516	CcSEcCtD
Etoricoxib—Fatigue—Lisinopril—systemic scleroderma	0.000224	0.000515	CcSEcCtD
Etoricoxib—Shock—Mycophenolate mofetil—systemic scleroderma	0.000224	0.000515	CcSEcCtD
Etoricoxib—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000223	0.000513	CcSEcCtD
Etoricoxib—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000223	0.000512	CcSEcCtD
Etoricoxib—Hypersensitivity—Leflunomide—systemic scleroderma	0.000222	0.000512	CcSEcCtD
Etoricoxib—Pancreatitis—Methotrexate—systemic scleroderma	0.000222	0.000511	CcSEcCtD
Etoricoxib—Constipation—Lisinopril—systemic scleroderma	0.000222	0.000511	CcSEcCtD
Etoricoxib—Pain—Lisinopril—systemic scleroderma	0.000222	0.000511	CcSEcCtD
Etoricoxib—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000221	0.000508	CcSEcCtD
Etoricoxib—Diarrhoea—Azathioprine—systemic scleroderma	0.000219	0.000504	CcSEcCtD
Etoricoxib—Haemoglobin—Prednisone—systemic scleroderma	0.000218	0.000502	CcSEcCtD
Etoricoxib—Nausea—Captopril—systemic scleroderma	0.000218	0.000501	CcSEcCtD
Etoricoxib—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000217	0.0005	CcSEcCtD
Etoricoxib—Haemorrhage—Prednisone—systemic scleroderma	0.000217	0.000499	CcSEcCtD
Etoricoxib—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000217	0.000499	CcSEcCtD
Etoricoxib—Asthenia—Leflunomide—systemic scleroderma	0.000217	0.000499	CcSEcCtD
Etoricoxib—Hallucination—Prednisone—systemic scleroderma	0.000216	0.000497	CcSEcCtD
Etoricoxib—MAPK14—VEGFA-VEGFR2 Pathway—NOS3—systemic scleroderma	0.000215	0.00326	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—SELP—systemic scleroderma	0.000214	0.00324	CbGpPWpGaD
Etoricoxib—Feeling abnormal—Lisinopril—systemic scleroderma	0.000214	0.000492	CcSEcCtD
Etoricoxib—Pruritus—Leflunomide—systemic scleroderma	0.000214	0.000492	CcSEcCtD
Etoricoxib—Connective tissue disorder—Prednisone—systemic scleroderma	0.000213	0.000491	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000212	0.000488	CcSEcCtD
Etoricoxib—Dizziness—Azathioprine—systemic scleroderma	0.000211	0.000487	CcSEcCtD
Etoricoxib—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.00021	0.000484	CcSEcCtD
Etoricoxib—MAPK14—TCR Signaling Pathway—IL1B—systemic scleroderma	0.00021	0.00318	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—IL1A—systemic scleroderma	0.000208	0.00314	CbGpPWpGaD
Etoricoxib—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000207	0.000477	CcSEcCtD
Etoricoxib—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000207	0.000476	CcSEcCtD
Etoricoxib—Asthenia—Mycophenolic acid—systemic scleroderma	0.000207	0.000476	CcSEcCtD
Etoricoxib—Diarrhoea—Leflunomide—systemic scleroderma	0.000207	0.000476	CcSEcCtD
Etoricoxib—Urticaria—Lisinopril—systemic scleroderma	0.000206	0.000474	CcSEcCtD
Etoricoxib—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000206	0.000473	CcSEcCtD
Etoricoxib—Abdominal pain—Lisinopril—systemic scleroderma	0.000205	0.000472	CcSEcCtD
Etoricoxib—Pruritus—Mycophenolic acid—systemic scleroderma	0.000204	0.000469	CcSEcCtD
Etoricoxib—MAPK14—Developmental Biology—RHOB—systemic scleroderma	0.000204	0.00308	CbGpPWpGaD
Etoricoxib—Vomiting—Azathioprine—systemic scleroderma	0.000203	0.000468	CcSEcCtD
Etoricoxib—MAPK14—Signaling by VEGF—NOS3—systemic scleroderma	0.000203	0.00307	CbGpPWpGaD
Etoricoxib—Pneumonia—Methotrexate—systemic scleroderma	0.000203	0.000467	CcSEcCtD
Etoricoxib—Eye disorder—Prednisone—systemic scleroderma	0.000203	0.000467	CcSEcCtD
Etoricoxib—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000203	0.000466	CcSEcCtD
Etoricoxib—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000202	0.000465	CcSEcCtD
Etoricoxib—Infestation—Methotrexate—systemic scleroderma	0.000202	0.000465	CcSEcCtD
Etoricoxib—Infestation NOS—Methotrexate—systemic scleroderma	0.000202	0.000465	CcSEcCtD
Etoricoxib—Rash—Azathioprine—systemic scleroderma	0.000202	0.000464	CcSEcCtD
Etoricoxib—Dermatitis—Azathioprine—systemic scleroderma	0.000201	0.000464	CcSEcCtD
Etoricoxib—Flushing—Prednisone—systemic scleroderma	0.000201	0.000463	CcSEcCtD
Etoricoxib—Headache—Azathioprine—systemic scleroderma	0.0002	0.000461	CcSEcCtD
Etoricoxib—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.0002	0.000461	CcSEcCtD
Etoricoxib—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.0002	0.000461	CcSEcCtD
Etoricoxib—MAPK14—Hemostasis—RHOB—systemic scleroderma	0.0002	0.00302	CbGpPWpGaD
Etoricoxib—Dizziness—Leflunomide—systemic scleroderma	0.0002	0.00046	CcSEcCtD
Etoricoxib—Renal failure—Methotrexate—systemic scleroderma	0.000198	0.000457	CcSEcCtD
Etoricoxib—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000198	0.000455	CcSEcCtD
Etoricoxib—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000197	0.000454	CcSEcCtD
Etoricoxib—Stomatitis—Methotrexate—systemic scleroderma	0.000197	0.000453	CcSEcCtD
Etoricoxib—Angiopathy—Prednisone—systemic scleroderma	0.000197	0.000453	CcSEcCtD
Etoricoxib—Conjunctivitis—Methotrexate—systemic scleroderma	0.000196	0.000452	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000196	0.000452	CcSEcCtD
Etoricoxib—Immune system disorder—Prednisone—systemic scleroderma	0.000196	0.000451	CcSEcCtD
Etoricoxib—Pain—Mycophenolate mofetil—systemic scleroderma	0.000194	0.000447	CcSEcCtD
Etoricoxib—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000194	0.000447	CcSEcCtD
Etoricoxib—Arrhythmia—Prednisone—systemic scleroderma	0.000194	0.000446	CcSEcCtD
Etoricoxib—Haematuria—Methotrexate—systemic scleroderma	0.000192	0.000443	CcSEcCtD
Etoricoxib—Vomiting—Leflunomide—systemic scleroderma	0.000192	0.000442	CcSEcCtD
Etoricoxib—Alopecia—Prednisone—systemic scleroderma	0.000192	0.000441	CcSEcCtD
Etoricoxib—Hypersensitivity—Lisinopril—systemic scleroderma	0.000191	0.00044	CcSEcCtD
Etoricoxib—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000191	0.00044	CcSEcCtD
Etoricoxib—Dizziness—Mycophenolic acid—systemic scleroderma	0.00019	0.000438	CcSEcCtD
Etoricoxib—Epistaxis—Methotrexate—systemic scleroderma	0.00019	0.000438	CcSEcCtD
Etoricoxib—MAPK14—Toll-like Receptor Signaling Pathway—IL1B—systemic scleroderma	0.00019	0.00288	CbGpPWpGaD
Etoricoxib—Rash—Leflunomide—systemic scleroderma	0.00019	0.000438	CcSEcCtD
Etoricoxib—Dermatitis—Leflunomide—systemic scleroderma	0.00019	0.000438	CcSEcCtD
Etoricoxib—Mental disorder—Prednisone—systemic scleroderma	0.00019	0.000437	CcSEcCtD
Etoricoxib—Nausea—Azathioprine—systemic scleroderma	0.00019	0.000437	CcSEcCtD
Etoricoxib—Headache—Leflunomide—systemic scleroderma	0.000189	0.000435	CcSEcCtD
Etoricoxib—Malnutrition—Prednisone—systemic scleroderma	0.000189	0.000435	CcSEcCtD
Etoricoxib—Erythema—Prednisone—systemic scleroderma	0.000189	0.000435	CcSEcCtD
Etoricoxib—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000187	0.000431	CcSEcCtD
Etoricoxib—Asthenia—Lisinopril—systemic scleroderma	0.000186	0.000428	CcSEcCtD
Etoricoxib—MAPK14—Senescence and Autophagy in Cancer—IL1B—systemic scleroderma	0.000186	0.00281	CbGpPWpGaD
Etoricoxib—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000186	0.000428	CcSEcCtD
Etoricoxib—Pruritus—Lisinopril—systemic scleroderma	0.000184	0.000423	CcSEcCtD
Etoricoxib—Vomiting—Mycophenolic acid—systemic scleroderma	0.000183	0.000422	CcSEcCtD
Etoricoxib—Haemoglobin—Methotrexate—systemic scleroderma	0.000182	0.000419	CcSEcCtD
Etoricoxib—MAPK14—Hemostasis—CSK—systemic scleroderma	0.000182	0.00275	CbGpPWpGaD
Etoricoxib—Rash—Mycophenolic acid—systemic scleroderma	0.000182	0.000418	CcSEcCtD
Etoricoxib—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000181	0.000418	CcSEcCtD
Etoricoxib—Hepatitis—Methotrexate—systemic scleroderma	0.000181	0.000417	CcSEcCtD
Etoricoxib—Haemorrhage—Methotrexate—systemic scleroderma	0.000181	0.000417	CcSEcCtD
Etoricoxib—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000181	0.000416	CcSEcCtD
Etoricoxib—PTGS2—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.00018	0.00273	CbGpPWpGaD
Etoricoxib—Headache—Mycophenolic acid—systemic scleroderma	0.00018	0.000415	CcSEcCtD
Etoricoxib—Pharyngitis—Methotrexate—systemic scleroderma	0.00018	0.000414	CcSEcCtD
Etoricoxib—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.00018	0.000414	CcSEcCtD
Etoricoxib—Nausea—Leflunomide—systemic scleroderma	0.000179	0.000413	CcSEcCtD
Etoricoxib—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000179	0.000412	CcSEcCtD
Etoricoxib—Vision blurred—Prednisone—systemic scleroderma	0.000178	0.00041	CcSEcCtD
Etoricoxib—Urethral disorder—Methotrexate—systemic scleroderma	0.000178	0.000409	CcSEcCtD
Etoricoxib—Diarrhoea—Lisinopril—systemic scleroderma	0.000177	0.000409	CcSEcCtD
Etoricoxib—Visual impairment—Methotrexate—systemic scleroderma	0.000175	0.000402	CcSEcCtD
Etoricoxib—Anaemia—Prednisone—systemic scleroderma	0.000174	0.000402	CcSEcCtD
Etoricoxib—Agitation—Prednisone—systemic scleroderma	0.000173	0.000399	CcSEcCtD
Etoricoxib—MAPK14—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—systemic scleroderma	0.000173	0.00261	CbGpPWpGaD
Etoricoxib—Angioedema—Prednisone—systemic scleroderma	0.000172	0.000397	CcSEcCtD
Etoricoxib—Dizziness—Lisinopril—systemic scleroderma	0.000172	0.000395	CcSEcCtD
Etoricoxib—Erythema multiforme—Methotrexate—systemic scleroderma	0.000171	0.000394	CcSEcCtD
Etoricoxib—Nausea—Mycophenolic acid—systemic scleroderma	0.000171	0.000394	CcSEcCtD
Etoricoxib—MAPK14—Hemostasis—ITGAM—systemic scleroderma	0.000171	0.00259	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular responses to stress—IL1A—systemic scleroderma	0.000171	0.00258	CbGpPWpGaD
Etoricoxib—Eye disorder—Methotrexate—systemic scleroderma	0.000169	0.00039	CcSEcCtD
Etoricoxib—Tinnitus—Methotrexate—systemic scleroderma	0.000169	0.000389	CcSEcCtD
Etoricoxib—Cardiac disorder—Methotrexate—systemic scleroderma	0.000168	0.000387	CcSEcCtD
Etoricoxib—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000167	0.000386	CcSEcCtD
Etoricoxib—Vomiting—Lisinopril—systemic scleroderma	0.000165	0.00038	CcSEcCtD
Etoricoxib—Angiopathy—Methotrexate—systemic scleroderma	0.000164	0.000379	CcSEcCtD
Etoricoxib—Immune system disorder—Methotrexate—systemic scleroderma	0.000164	0.000377	CcSEcCtD
Etoricoxib—Rash—Lisinopril—systemic scleroderma	0.000164	0.000377	CcSEcCtD
Etoricoxib—MAPK14—TCR Signaling Pathway—TGFB1—systemic scleroderma	0.000164	0.00247	CbGpPWpGaD
Etoricoxib—Dermatitis—Lisinopril—systemic scleroderma	0.000163	0.000376	CcSEcCtD
Etoricoxib—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000163	0.000376	CcSEcCtD
Etoricoxib—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000163	0.000375	CcSEcCtD
Etoricoxib—Hypertension—Prednisone—systemic scleroderma	0.000163	0.000375	CcSEcCtD
Etoricoxib—Headache—Lisinopril—systemic scleroderma	0.000162	0.000374	CcSEcCtD
Etoricoxib—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000161	0.00037	CcSEcCtD
Etoricoxib—Arthralgia—Prednisone—systemic scleroderma	0.000161	0.00037	CcSEcCtD
Etoricoxib—MAPK14—Corticotropin-releasing hormone—TGFB1—systemic scleroderma	0.000161	0.00243	CbGpPWpGaD
Etoricoxib—Anxiety—Prednisone—systemic scleroderma	0.00016	0.000369	CcSEcCtD
Etoricoxib—Alopecia—Methotrexate—systemic scleroderma	0.00016	0.000369	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.00016	0.000367	CcSEcCtD
Etoricoxib—Mental disorder—Methotrexate—systemic scleroderma	0.000159	0.000366	CcSEcCtD
Etoricoxib—Malnutrition—Methotrexate—systemic scleroderma	0.000158	0.000363	CcSEcCtD
Etoricoxib—Erythema—Methotrexate—systemic scleroderma	0.000158	0.000363	CcSEcCtD
Etoricoxib—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000155	0.000358	CcSEcCtD
Etoricoxib—MAPK14—EGF/EGFR Signaling Pathway—NOS3—systemic scleroderma	0.000155	0.00234	CbGpPWpGaD
Etoricoxib—Dysgeusia—Methotrexate—systemic scleroderma	0.000154	0.000356	CcSEcCtD
Etoricoxib—Nausea—Lisinopril—systemic scleroderma	0.000154	0.000355	CcSEcCtD
Etoricoxib—Anaphylactic shock—Prednisone—systemic scleroderma	0.000154	0.000355	CcSEcCtD
Etoricoxib—Oedema—Prednisone—systemic scleroderma	0.000154	0.000355	CcSEcCtD
Etoricoxib—MAPK14—Innate Immune System—ITGAM—systemic scleroderma	0.000154	0.00233	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—CD247—systemic scleroderma	0.000154	0.00233	CbGpPWpGaD
Etoricoxib—Infection—Prednisone—systemic scleroderma	0.000153	0.000352	CcSEcCtD
Etoricoxib—Shock—Prednisone—systemic scleroderma	0.000152	0.000349	CcSEcCtD
Etoricoxib—Nervous system disorder—Prednisone—systemic scleroderma	0.000151	0.000348	CcSEcCtD
Etoricoxib—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.00015	0.000346	CcSEcCtD
Etoricoxib—Skin disorder—Prednisone—systemic scleroderma	0.00015	0.000345	CcSEcCtD
Etoricoxib—Vision blurred—Methotrexate—systemic scleroderma	0.000149	0.000342	CcSEcCtD
Etoricoxib—MAPK14—Regulation of toll-like receptor signaling pathway—IL1B—systemic scleroderma	0.000149	0.00225	CbGpPWpGaD
Etoricoxib—Anorexia—Prednisone—systemic scleroderma	0.000147	0.000338	CcSEcCtD
Etoricoxib—Anaemia—Methotrexate—systemic scleroderma	0.000146	0.000336	CcSEcCtD
Etoricoxib—MAPK14—Senescence and Autophagy in Cancer—TGFB1—systemic scleroderma	0.000145	0.00219	CbGpPWpGaD
Etoricoxib—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000144	0.000333	CcSEcCtD
Etoricoxib—MAPK14—Innate Immune System—TNFAIP3—systemic scleroderma	0.000144	0.00218	CbGpPWpGaD
Etoricoxib—Rash—Mycophenolate mofetil—systemic scleroderma	0.000143	0.00033	CcSEcCtD
Etoricoxib—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000143	0.00033	CcSEcCtD
Etoricoxib—PTGS2—Spinal Cord Injury—CCL2—systemic scleroderma	0.000143	0.00216	CbGpPWpGaD
Etoricoxib—Headache—Mycophenolate mofetil—systemic scleroderma	0.000142	0.000328	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.00014	0.000323	CcSEcCtD
Etoricoxib—Insomnia—Prednisone—systemic scleroderma	0.000139	0.000321	CcSEcCtD
Etoricoxib—Cough—Methotrexate—systemic scleroderma	0.000138	0.000317	CcSEcCtD
Etoricoxib—PTGS2—Selenium Micronutrient Network—IL1B—systemic scleroderma	0.000137	0.00207	CbGpPWpGaD
Etoricoxib—Dyspepsia—Prednisone—systemic scleroderma	0.000136	0.000312	CcSEcCtD
Etoricoxib—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000135	0.000311	CcSEcCtD
Etoricoxib—MAPK14—Gene Expression—SMAD7—systemic scleroderma	0.000135	0.00204	CbGpPWpGaD
Etoricoxib—Chest pain—Methotrexate—systemic scleroderma	0.000134	0.000309	CcSEcCtD
Etoricoxib—Arthralgia—Methotrexate—systemic scleroderma	0.000134	0.000309	CcSEcCtD
Etoricoxib—Decreased appetite—Prednisone—systemic scleroderma	0.000134	0.000308	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000133	0.000307	CcSEcCtD
Etoricoxib—Fatigue—Prednisone—systemic scleroderma	0.000133	0.000306	CcSEcCtD
Etoricoxib—Constipation—Prednisone—systemic scleroderma	0.000132	0.000303	CcSEcCtD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	0.00013	0.00197	CbGpPWpGaD
Etoricoxib—Confusional state—Methotrexate—systemic scleroderma	0.00013	0.000299	CcSEcCtD
Etoricoxib—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000129	0.000296	CcSEcCtD
Etoricoxib—Infection—Methotrexate—systemic scleroderma	0.000128	0.000294	CcSEcCtD
Etoricoxib—MAPK14—MAPK Signaling Pathway—IL1B—systemic scleroderma	0.000128	0.00193	CbGpPWpGaD
Etoricoxib—Feeling abnormal—Prednisone—systemic scleroderma	0.000127	0.000292	CcSEcCtD
Etoricoxib—Nervous system disorder—Methotrexate—systemic scleroderma	0.000126	0.000291	CcSEcCtD
Etoricoxib—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000126	0.00029	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000126	0.00029	CcSEcCtD
Etoricoxib—MAPK14—Gene Expression—TNFSF13—systemic scleroderma	0.000125	0.00189	CbGpPWpGaD
Etoricoxib—Skin disorder—Methotrexate—systemic scleroderma	0.000125	0.000288	CcSEcCtD
Etoricoxib—Anorexia—Methotrexate—systemic scleroderma	0.000123	0.000283	CcSEcCtD
Etoricoxib—Urticaria—Prednisone—systemic scleroderma	0.000122	0.000282	CcSEcCtD
Etoricoxib—Abdominal pain—Prednisone—systemic scleroderma	0.000122	0.00028	CcSEcCtD
Etoricoxib—MAPK14—TGF-beta Signaling Pathway—TGFB1—systemic scleroderma	0.00012	0.00182	CbGpPWpGaD
Etoricoxib—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000117	0.00027	CcSEcCtD
Etoricoxib—Insomnia—Methotrexate—systemic scleroderma	0.000116	0.000268	CcSEcCtD
Etoricoxib—Dyspnoea—Methotrexate—systemic scleroderma	0.000115	0.000264	CcSEcCtD
Etoricoxib—Somnolence—Methotrexate—systemic scleroderma	0.000114	0.000264	CcSEcCtD
Etoricoxib—Hypersensitivity—Prednisone—systemic scleroderma	0.000113	0.000261	CcSEcCtD
Etoricoxib—Dyspepsia—Methotrexate—systemic scleroderma	0.000113	0.000261	CcSEcCtD
Etoricoxib—Decreased appetite—Methotrexate—systemic scleroderma	0.000112	0.000258	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000111	0.000256	CcSEcCtD
Etoricoxib—Fatigue—Methotrexate—systemic scleroderma	0.000111	0.000256	CcSEcCtD
Etoricoxib—Asthenia—Prednisone—systemic scleroderma	0.000111	0.000254	CcSEcCtD
Etoricoxib—Pain—Methotrexate—systemic scleroderma	0.00011	0.000253	CcSEcCtD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.00011	0.00166	CbGpPWpGaD
Etoricoxib—Pruritus—Prednisone—systemic scleroderma	0.000109	0.000251	CcSEcCtD
Etoricoxib—PTGS2—Spinal Cord Injury—IL1B—systemic scleroderma	0.000108	0.00164	CbGpPWpGaD
Etoricoxib—Feeling abnormal—Methotrexate—systemic scleroderma	0.000106	0.000244	CcSEcCtD
Etoricoxib—Diarrhoea—Prednisone—systemic scleroderma	0.000105	0.000243	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000105	0.000242	CcSEcCtD
Etoricoxib—Urticaria—Methotrexate—systemic scleroderma	0.000102	0.000235	CcSEcCtD
Etoricoxib—PTGS2—Spinal Cord Injury—MMP9—systemic scleroderma	0.000102	0.00154	CbGpPWpGaD
Etoricoxib—Dizziness—Prednisone—systemic scleroderma	0.000102	0.000235	CcSEcCtD
Etoricoxib—Abdominal pain—Methotrexate—systemic scleroderma	0.000102	0.000234	CcSEcCtD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	0.000101	0.00153	CbGpPWpGaD
Etoricoxib—MAPK14—MAPK Signaling Pathway—TGFB1—systemic scleroderma	9.92e-05	0.0015	CbGpPWpGaD
Etoricoxib—Vomiting—Prednisone—systemic scleroderma	9.79e-05	0.000226	CcSEcCtD
Etoricoxib—Rash—Prednisone—systemic scleroderma	9.71e-05	0.000224	CcSEcCtD
Etoricoxib—Dermatitis—Prednisone—systemic scleroderma	9.7e-05	0.000223	CcSEcCtD
Etoricoxib—Headache—Prednisone—systemic scleroderma	9.65e-05	0.000222	CcSEcCtD
Etoricoxib—MAPK14—Immune System—CSK—systemic scleroderma	9.54e-05	0.00144	CbGpPWpGaD
Etoricoxib—Hypersensitivity—Methotrexate—systemic scleroderma	9.49e-05	0.000218	CcSEcCtD
Etoricoxib—MAPK14—Immune System—IRF5—systemic scleroderma	9.38e-05	0.00142	CbGpPWpGaD
Etoricoxib—Asthenia—Methotrexate—systemic scleroderma	9.24e-05	0.000213	CcSEcCtD
Etoricoxib—Nausea—Prednisone—systemic scleroderma	9.15e-05	0.000211	CcSEcCtD
Etoricoxib—Pruritus—Methotrexate—systemic scleroderma	9.11e-05	0.00021	CcSEcCtD
Etoricoxib—MAPK14—Immune System—ITGAM—systemic scleroderma	8.97e-05	0.00136	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—IRF8—systemic scleroderma	8.97e-05	0.00136	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CD247—systemic scleroderma	8.97e-05	0.00136	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	8.96e-05	0.00135	CbGpPWpGaD
Etoricoxib—Diarrhoea—Methotrexate—systemic scleroderma	8.81e-05	0.000203	CcSEcCtD
Etoricoxib—MAPK14—Signaling Pathways—SMAD7—systemic scleroderma	8.75e-05	0.00132	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—MMP1—systemic scleroderma	8.57e-05	0.0013	CbGpPWpGaD
Etoricoxib—Dizziness—Methotrexate—systemic scleroderma	8.51e-05	0.000196	CcSEcCtD
Etoricoxib—PTGS2—Spinal Cord Injury—TGFB1—systemic scleroderma	8.41e-05	0.00127	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—TNFAIP3—systemic scleroderma	8.4e-05	0.00127	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	8.3e-05	0.00126	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—BLK—systemic scleroderma	8.3e-05	0.00125	CbGpPWpGaD
Etoricoxib—Vomiting—Methotrexate—systemic scleroderma	8.19e-05	0.000188	CcSEcCtD
Etoricoxib—Rash—Methotrexate—systemic scleroderma	8.12e-05	0.000187	CcSEcCtD
Etoricoxib—Dermatitis—Methotrexate—systemic scleroderma	8.11e-05	0.000187	CcSEcCtD
Etoricoxib—Headache—Methotrexate—systemic scleroderma	8.07e-05	0.000186	CcSEcCtD
Etoricoxib—PTGS2—Disease—SMAD7—systemic scleroderma	7.98e-05	0.00121	CbGpPWpGaD
Etoricoxib—MAPK14—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	7.97e-05	0.00121	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	7.95e-05	0.0012	CbGpPWpGaD
Etoricoxib—Nausea—Methotrexate—systemic scleroderma	7.65e-05	0.000176	CcSEcCtD
Etoricoxib—MAPK14—Gene Expression—CTGF—systemic scleroderma	7.44e-05	0.00113	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—TGFBI—systemic scleroderma	7.3e-05	0.0011	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	7.25e-05	0.0011	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CTLA4—systemic scleroderma	6.8e-05	0.00103	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—RHOB—systemic scleroderma	6.77e-05	0.00102	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—MMP2—systemic scleroderma	6.76e-05	0.00102	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—HSPG2—systemic scleroderma	6.38e-05	0.000966	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—NOS3—systemic scleroderma	6.21e-05	0.00094	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	6.2e-05	0.000937	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CSK—systemic scleroderma	6.17e-05	0.000933	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	6.03e-05	0.000912	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—HSPG2—systemic scleroderma	5.82e-05	0.000881	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	5.72e-05	0.000865	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CSK—systemic scleroderma	5.63e-05	0.000851	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—HLA-DQB1—systemic scleroderma	5.6e-05	0.000846	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	5.5e-05	0.000831	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—IL1A—systemic scleroderma	5.32e-05	0.000804	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CD247—systemic scleroderma	5.29e-05	0.0008	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CD40LG—systemic scleroderma	5.28e-05	0.000799	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—MMP9—systemic scleroderma	5.08e-05	0.000768	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—HSPG2—systemic scleroderma	4.88e-05	0.000738	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	4.7e-05	0.00071	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—HSPG2—systemic scleroderma	4.59e-05	0.000694	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—TGFB1—systemic scleroderma	4.19e-05	0.000633	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—TGFB1—systemic scleroderma	4.11e-05	0.000621	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—CTGF—systemic scleroderma	3.7e-05	0.000559	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—HSPG2—systemic scleroderma	3.54e-05	0.000536	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—CTGF—systemic scleroderma	3.48e-05	0.000526	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—EDN1—systemic scleroderma	3.46e-05	0.000523	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—HSPG2—systemic scleroderma	3.26e-05	0.000493	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—HSPG2—systemic scleroderma	3.23e-05	0.000489	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—IL1B—systemic scleroderma	2.77e-05	0.000419	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—HSPG2—systemic scleroderma	2.76e-05	0.000417	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CTGF—systemic scleroderma	2.68e-05	0.000406	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CTGF—systemic scleroderma	2.47e-05	0.000373	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CTGF—systemic scleroderma	2.45e-05	0.00037	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CCL2—systemic scleroderma	2.36e-05	0.000357	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—HSPG2—systemic scleroderma	2.13e-05	0.000322	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—NOS3—systemic scleroderma	2.11e-05	0.000319	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CTGF—systemic scleroderma	2.09e-05	0.000316	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—NOS3—systemic scleroderma	1.92e-05	0.000291	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MMP9—systemic scleroderma	1.69e-05	0.000256	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CTGF—systemic scleroderma	1.61e-05	0.000244	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—NOS3—systemic scleroderma	1.61e-05	0.000243	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—NOS3—systemic scleroderma	1.51e-05	0.000229	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—TGFB1—systemic scleroderma	1.39e-05	0.000211	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—TGFB1—systemic scleroderma	1.27e-05	0.000192	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—NOS3—systemic scleroderma	1.17e-05	0.000177	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—NOS3—systemic scleroderma	1.07e-05	0.000163	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—NOS3—systemic scleroderma	1.07e-05	0.000161	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—NOS3—systemic scleroderma	9.11e-06	0.000138	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—NOS3—systemic scleroderma	7.03e-06	0.000106	CbGpPWpGaD
